Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:05:13 EDT Tue 23 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:LXRX from 2023-04-24 to 2024-04-23 - 43 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-18 08:01U:LXRXNews ReleaseLexicon Pharmaceuticals to Host 2024 Investor Day
2024-04-03 08:00U:LXRXNews ReleaseLexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
2024-03-25 09:21U:LXRXNews ReleaseClinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo
2024-03-12 08:00U:LXRXNews ReleaseNew Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease
2024-03-11 07:15U:LXRXNews ReleaseLexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update
2024-03-11 07:05U:LXRXNews ReleaseLexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities
2024-03-11 07:00U:LXRXNews ReleaseLexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA
2024-01-08 07:00U:LXRXNews ReleaseLexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare Conference
2023-12-21 16:15U:LXRXNews ReleaseLexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare Conference
2023-11-30 07:30U:LXRXNews ReleaseLexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
2023-11-22 07:30U:LXRXNews ReleaseLexicon Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference and the 6th Annual Evercore ISI HealthCONx Conference
2023-11-12 14:10U:LXRXNews ReleaseINPEFA ‚ ® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data
2023-11-10 16:01U:LXRXNews ReleaseLexicon Pharmaceuticals to Participate in the Jefferies London Healthcare Conference
2023-11-08 07:00U:LXRXNews ReleaseLexicon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
2023-11-03 09:00U:LXRXNews ReleaseLexicon Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call and Webcast on November 8, 2023
2023-11-02 09:00U:LXRXNews ReleaseData on Early Clinical Benefit for INPEFA ‚ ® (Sotagliflozin) Will Be Among Five Lexicon-Sponsored Presentations at the American Heart Association Scientific Sessions 2023
2023-11-01 09:00U:LXRXNews ReleaseINPEFA ‚ ® (Sotagliflozin) Receives Coverage From Express Scripts on Its Basic and High Performance Formularies for Commercially Insured Patients
2023-10-31 16:01U:LXRXNews ReleaseLexicon Strengthens Management Team With Two New Executives
2023-10-30 16:01U:LXRXNews ReleaseNew Data Relating to Sotagliflozin to be Presented at the American Society of Nephrology (ASN) Kidney Week 2023 Annual Meeting
2023-10-17 16:01U:LXRXNews ReleaseData From Two Studies Demonstrating Positive Financial Impact of INPEFA ‚ ® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting
2023-10-11 09:00U:LXRXNews ReleaseData Demonstrating Financial Impact of INPEFA ‚ ® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting
2023-10-09 16:01U:LXRXNews ReleaseINPEFA ‚ ® (Sotagliflozin) Receives Preferred Formulary Status With Express Scripts For Medicare Patients
2023-10-09 08:00U:LXRXNews ReleaseTom Garner Joins Lexicon as Senior Vice President and Chief Commercial Officer
2023-09-28 09:00U:LXRXNews ReleaseLexicon to Present Post Hoc Analysis of Scored Clinical Trial at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2023
2023-09-26 09:00U:LXRXNews ReleaseLexicon to Present Study Results Relating to Sotagliflozin and LX9211 at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD)
2023-09-07 16:30U:LXRXNews ReleaseLexicon Pharmaceuticals to Participate in the H.C. Wainwright & Co. 25th Annual Global Investment Conference
2023-09-07 09:00U:LXRXNews ReleaseLexicon Announces Series of Presentations Relating to LX9211, Its Investigational Drug for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)
2023-08-21 09:00U:LXRXNews ReleaseLexicon to Present Analyses of INPEFA ¢ „ ¢ (sotagliflozin) Clinical Study Results and Changing Patterns of Heart Failure Diagnoses at the European Society of Cardiology (ESC) Congress 2023
2023-08-08 09:00U:LXRXNews ReleasePublished Analysis of Sotagliflozin (INPEFA(TM)) Clinical Data Demonstrates Significant Reductions in the Risk of Hospital Readmissions for Heart Failure
2023-08-03 16:01U:LXRXNews ReleaseLexicon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
2023-07-28 16:01U:LXRXNews ReleaseLexicon Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 3, 2023
2023-07-28 08:00U:LXRXNews ReleaseLexicon Elects Diane E. Sullivan to Board of Directors
2023-06-23 20:45U:LXRXNews ReleaseLexicon Announces Planned Advancement of LX9211 Into Late-Stage Development
2023-06-20 08:00U:LXRXNews ReleaseLexicon to Present Study Results Relating to LX9211 and INPEFA ¢ „ ¢ (Sotagliflozin) at the American Diabetes Association ¢ € ™s 83rd Scientific Sessions
2023-06-15 17:01U:LXRXNews ReleaseUPDATE: Lexicon Announces FDA Approval of INPEFA ¢ „ ¢ (sotagliflozin) for Treatment of Heart Failure
2023-06-06 16:01U:LXRXNews ReleaseLexicon Pharmaceuticals to Participate in the Jefferies 2023 Global Healthcare Conference
2023-06-05 16:01U:LXRXNews ReleaseLexicon Announces Closing of Public Offering and Concurrent Private Placement, Including Full Exercise of Options to Purchase Additional Shares
2023-06-01 08:00U:LXRXNews ReleaseLexicon Announces Pricing of $125 Million Public Offering and Concurrent Private Placement
2023-05-31 16:01U:LXRXNews ReleaseLexicon Announces Proposed Public Offering of Common Stock
2023-05-26 16:05U:LXRXNews ReleaseLexicon Announces FDA Approval of INPEFA ¢ „ ¢ (sotagliflozin) for Treatment of Heart Failure
2023-05-10 16:30U:LXRXNews ReleaseNew Analysis Finds Sotagliflozin to Be a Cost-Effective Treatment at Commonly Accepted Willingness-to-Pay Threshold in Patients with Worsening Heart Failure
2023-05-02 16:00U:LXRXNews ReleaseLexicon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
2023-04-28 16:00U:LXRXNews ReleaseLexicon Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 2, 2023